Tharimmune Net Income From Continuing Ops from 2010 to 2025

THAR Stock   1.44  0.11  7.10%   
Tharimmune Net Loss yearly trend continues to be relatively stable with very little volatility. Net Loss is likely to grow to about -8 M this year. During the period from 2010 to 2025, Tharimmune Net Loss destribution of quarterly values had range of 7.8 M from its regression line and mean deviation of  2,580,097. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-8.4 M
Current Value
-8 M
Quarterly Volatility
3.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Tharimmune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tharimmune's main balance sheet or income statement drivers, such as Net Interest Income of 128.6 K, Interest Expense of 18 K or Selling General Administrative of 7.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.0688. Tharimmune financial statements analysis is a perfect complement when working with Tharimmune Valuation or Volatility modules.
  
Check out the analysis of Tharimmune Correlation against competitors.
To learn how to invest in Tharimmune Stock, please use our How to Invest in Tharimmune guide.

Latest Tharimmune's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Tharimmune over the last few years. It is Tharimmune's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tharimmune's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Tharimmune Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(3,376,628)
Geometric Mean2,470,124
Coefficient Of Variation(91.77)
Mean Deviation2,580,097
Median(1,525,474)
Standard Deviation3,098,702
Sample Variance9.6T
Range7.8M
R-Value(0.78)
Mean Square Error4.1T
R-Squared0.60
Significance0.0004
Slope(504,889)
Total Sum of Squares144T

Tharimmune Net Income From Continuing Ops History

2025-8 M
2024-8.4 M
2023-9.3 M
2022-8.5 M
2021-2.2 M
2020-2.4 M

About Tharimmune Financial Statements

Tharimmune shareholders use historical fundamental indicators, such as Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Tharimmune investors may analyze each financial statement separately, they are all interrelated. The changes in Tharimmune's assets and liabilities, for example, are also reflected in the revenues and expenses on on Tharimmune's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-8.4 M-8 M

Pair Trading with Tharimmune

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tharimmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tharimmune will appreciate offsetting losses from the drop in the long position's value.

Moving together with Tharimmune Stock

  0.79CDIOW Cardio DiagnosticsPairCorr
  0.79ELVN Enliven TherapeuticsPairCorr

Moving against Tharimmune Stock

  0.8LUCD Lucid DiagnosticsPairCorr
  0.75WM Waste ManagementPairCorr
  0.56PG Procter GamblePairCorr
  0.54GE GE AerospacePairCorr
  0.33PLX Protalix BiotherapeuticsPairCorr
The ability to find closely correlated positions to Tharimmune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tharimmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tharimmune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tharimmune to buy it.
The correlation of Tharimmune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tharimmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tharimmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tharimmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Tharimmune Stock Analysis

When running Tharimmune's price analysis, check to measure Tharimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tharimmune is operating at the current time. Most of Tharimmune's value examination focuses on studying past and present price action to predict the probability of Tharimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tharimmune's price. Additionally, you may evaluate how the addition of Tharimmune to your portfolios can decrease your overall portfolio volatility.